Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | PYGB | P11216 | 2/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846614 | 0.93 | LMNA (0.46) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL31070840 | 0.92 | LMNA (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL8604152 | 0.91 | LMNA (0.45) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL15239320 | 0.90 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL3272285 | 0.89 | LMNA (0.51) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL28645147 | 0.88 | LMNA (0.46) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL1896532 | 0.87 | LMNA (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL2180644 | 0.87 | LMNA (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL6060585 | 0.87 | LMNA (0.45) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL29780374 | 0.87 | LMNA (0.45) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4587044-A | Linkage of proteins to nucleic acids | THE JOHNS HOPKINS UNIVERSITY (US) | 1986-05-06 | — | — | US | claimed |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| EP-0423839-B1 | Polynucleotides and probes useful in solution phase nucleic acid sandwich assay | BAYER AG (US) | 2001-08-16 | — | — | EP | disclosed |
| EP-0225807-B1 | Solution phase nucleic acid sandwich assay and polynucleotide probes useful therein | CHIRON CORP (US) | 1994-10-19 | — | — | EP | disclosed |
| US-5093232-A | Detection of dna sequences | CHIRON CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0423839-A2 | Polynucleotides and probes useful in solution phase nucleic acid sandwich assay | CHIRON CORPORATION (US) | 1991-04-24 | — | — | EP | disclosed |
| US-4910300-A | Adding additional nucleotide to modified nucleotide at | CHIRON CORPORATION (US) | 1990-03-20 | — | — | US | disclosed |
| EP-0225807-A2 | Solution phase nucleic acid sandwich assay and polynucleotide probes useful therein | CHIRON CORPORATION (US) | 1987-06-16 | — | — | EP | disclosed |
| US-4587044-A | Linkage of proteins to nucleic acids | THE JOHNS HOPKINS UNIVERSITY (US) | 1986-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | LMNA 144/4885MTOR 4145/4885THRB 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.